 |
Dimas K., Tsimplouli C., Anagnostopoulos A.K., Mahaira L., Iliopoulou E., Perez S., Vougas K., Tsangaris G. “The proteome profile of two cell lines and their xenografts isolated from a patient with clear cell sarcoma (soft tissue melanoma)” Cancer Genomics & Proteomics 5: 175-238 (2008).
View Paper
Vanessa Villard, Johann Meunier, Alexandre Vamvakides, Tangui Maurice, (2007). “Neuroprotective activity of ANAVEX 1-41, an aminotetrahydrofuran derivative acting as a mixed muscarinic/sigma-1 ligands, against amyloid beta(25-35) peptide toxicity in mice”. Poster presentation in Neuroscience 2007, Nov. 3-7 in San Diego, Calif.
Johann Meunier, Vanessa Villard, Julie Espallergues, Alexandre Vamvakides and Tangui Maurice, (2007). “Anti-amnesic and neuroprotective activities of ANAVEX 2-73, a new aminotetrahydrofuran derivative acting as a mixed muscarinic/sigma-1 ligands, in pharmacological and pathological models of amnesia”. Poster presentation in Neuroscience 2007, Nov. 3-7 in San Diego, Calif.
Mahaira G Louisa, Humaira Khan, Chrisiida Tsiblouli, Pantazis Panayotis, Karamitopoulou Evangelia, Vamvakides Alexandros, and Dimas Konstantinos (2007) "Anavex 7-1037, a novel small synthetic sigma ligand, induces apoptosis in human HCT116 colon cancer cells in vitro and suppression of HCT116 tumor growth in SCID mice." Poster Presentation in the 15th Euroconference on Apoptosis & 4th Training course on 'Concepts and Methods in Programmed Cell Death', October 26-31, 2007 in Portoroz, Slovenia.
Espallergues J., Lapalud P., Christopoulos A., Avlani V.A., Sexton P.M., Vamvakides A. and Maurice T., (2007). “Involvement of the sigma1 (s1) receptor in the antiamnesic, but not antidepressant-like, effects of the aminotetrahydrofuran derivative ANAVEX 1-41”. British Journal of Pharmacology.
Vanessa Villard, Julie Espallergues, Alexandre Vamvakides & Tangui Maurice, (2007). “Anti-amnesic and neuroprotective potentials of aminotetrahydrofuran derivatives, mixed muscarinic/sigma1 (s1) ligands, against amyloid beta25-35 peptide toxicity in mice”. Poster Presentation in the 8e Colloque de la Société des Neurosciences, May 22-25, Montpellier, France.
Julie Espallergues, Priscilla Lapalud, Alexandre Vamvakides, and Tangui Maurice, (2006), “Involvement of the sigma1 (s1) receptor in the anti-amnesic effects of the aminotetrahydrofuran derivative AE14”. Poster Presentation in Neuroscience 2006, October 14-18, Atlanta, USA.
Vamvakides A, Antoniou K, Daifoti Z., (2004). “Action mechanism of anticonvulsant and anti-immobility (forced swim) effects of 3', 4'-dihydro-N, N-dimethylspiro-[9H-fluorene-9, 2' (5'H) furane]-3'-methanamine (AE37F)”. Ann Pharm Fr.; 62(1):49-55 (French).
View abstract in PubMed
Vamvakides A., (2003). “Selective M1 muscarinic agonists: failure of therapeutic strategy against Alzheimer's disease or inappropriate tactics?”. Ann Pharm Fr.; 61(3):207-10 Review (French).
Vamvakides A., (2002). “Mechanism of action of tetrahydro-N, N-dimethyl-5, 5-diphenyl-3-furanemethanamine, a putative nootropic, anti-epileptic and antidepressant compound”. Ann Pharm Fr.; 60(6):415-22. (French)
Vamvakides A., (2002) “Anticonvulsant and forced swim anti-immobility effects of tetrahydro-N, N-dimethyl-2,2-diphenyl-3-furanemethanamine (AE37): common action mechanism?” Ann Pharm Fr.; 60(2):88-92. Review (French).
